SCHEMBL5181491

SCHEMBL5181491

COc1ccc(C=NNC(=S)Nc2ccc(C)cc2C)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX12 P18054 4/20 0.70
▸ GAA P10253 4/20 0.70
▸ NPSR1 Q6W5P4 2/20 0.70
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ NPC1 O15118 3/20 0.60
▸ RAB9A P51151 3/20 0.60
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ MAPT P10636 7/20 0.59
▸ HTT P42858 3/20 0.59
▸ LMNA P02545 3/20 0.56
▸ MAOA P21397 1/20 0.54
▸ RRM1 P23921 3/20 0.54
▸ RRM2 P31350 3/20 0.54
▸ RRM2B Q7LG56 3/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ STAT3 P40763 1/20 0.54
▸ STAT1 P42224 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5181488 1.00 ALOX12 (0.70) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5181869 0.85 ALOX12 (0.68) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5181864 0.85 ALOX12 (0.68) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5181464 0.85 ALOX12 (0.67) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5181467 0.85 ALOX12 (0.67) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5179591 0.83 GAA (0.61) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5179588 0.83 GAA (0.61) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5180461 0.82 MAPT (0.61) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL6848013 0.82 MAPT (0.61) ALOX12GAANPSR1SMN1; SMN2NPC1
SCHEMBL5180298 0.82 ALOX12 (0.60) ALOX12GAANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399159-A4 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2007-02-14 — — EP disclosed
US-6794400-B2 USE AS ANTICANCER AGENTS AND IN OTHER CONDITIONS INVOLVING ABNORMAL CELL PROLIFERATION SUCH AS RHEUMATOID ARTHRITIS CYTOVIA, INC. 2004-09-21 — — US disclosed
EP-1399159-A1 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2004-03-24 — — EP disclosed
US-20030045581-A1 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof DISCOVER GROWTH FUND, LLC (VI) 2003-03-06 — — US disclosed
WO-2002098420-A1 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2002-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045581-A1 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1- (arylcarbonyl) thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP3, CASP4 ALOX12 3136/4885GAA 2524/4885NPSR1 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback